Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Sachin Gopalkrishn Pai"'
Autor:
Austin Cadden, Thomas W. Butler, Daniel Cameron, Cathy Tinnea, Susan T. Owenby, Sachin Gopalkrishn Pai, Jennifer Young Pierce, Debra Wujcik, Moh’d Khushman
Publikováno v:
Journal of Clinical Oncology. 37:88-88
88 Background: Treatment of lung cancer has seen a paradigm shift in recent years. While the availability of newer treatment options such as targeted therapy and immunotherapy have provided new hope for better outcomes, this has added to the cost of
Autor:
Barbara Pro, Sachin Gopalkrishn Pai, Victoria M. Villaflor, W. Iams, Timothy Taxter, Francis J. Giles, Young Kwang Chae, R. Costa, Nisha Mohindra
Publikováno v:
Journal of Thoracic Oncology. 12:S1973-S1974
Autor:
Sachin Gopalkrishn Pai, Barbara Pro, Victoria M. Villaflor, Francis J. Giles, Young Kwang Chae, Nisha Mohindra, Timothy Taxter, R. Costa, W. Iams
Publikováno v:
Journal of Thoracic Oncology. 12:S1974
Autor:
Julia A. Elvin, Daniel T. Oberlin, Kyle Fedorchak, Sohail Balasubramanian, Benedito A. Carneiro, Alfred Rademaker, Sachin Gopalkrishn Pai, Nike Beaubier, Francis J. Giles, Joshua J. Meeks
Publikováno v:
Journal of Clinical Oncology. 35:397-397
397 Background: The genetic mechanisms associated with progression of high-risk non-muscle-invasive bladder cancer (HR-NMIBC) have not been described. We conducted next-generation sequencing (NGS) of HR-NMIBC and compared the genomic profiles of canc
Autor:
Massimo Cristofanilli, Ricardo Costa, Alfred Rademaker, Mark Agulnik, Sunandana Chandra, Aparna Kalyan, Francis J. Giles, Jason B. Kaplan, Sachin Gopalkrishn Pai, Victoria M. Villaflor, Benedito A. Carneiro, Young Kwang Chae, Maria Matsangou
Publikováno v:
Journal of Clinical Oncology. 34:3064-3064
3064Background: Clinical trials supported the FDA approval of anti-PD1 antibodies nivolumab and pembrolizumab for treatment of advanced melanoma, renal cell carcinoma, and non-small cell lung cance...
Autor:
Sunandana Chandra, Daniel Olson, Massimo Cristofanilli, Aparna Kalyan, Ricardo Costa, Benedito A. Carneiro, Mary F. Mulcahy, Nike Beaubier, Maria Matsangou, Young Kwang Chae, Francis J. Giles, Jason B. Kaplan, Sachin Gopalkrishn Pai
Publikováno v:
Journal of Clinical Oncology. 34:e23206-e23206
e23206Background: The paradigm in the treatment of cancer is changing such that, treatment based on molecular targets and associated pathways is at the forefront rather than chemotherapy. The ident...
Autor:
Alfred Rademaker, Jordan Berlin, Mark M. Zalupski, Mary F. Mulcahy, Sheetal Mehta Kircher, Al B. Benson, Crystal S. Denlinger, E. Gabriela Chiorean, Vaibhav Sahai, Halla Sayed Nimeiri, Steven J. Cohen, Sachin Gopalkrishn Pai
Publikováno v:
Journal of Clinical Oncology. 34:e15662-e15662
e15662Background: Pazopanib (Pazo) is an angiogenesis tyrosine kinase inhibitor(TKI) targeting VEGFR-1, -2, and -3; PDGFR-α, -β; and c-Kit. Pazo has shown activity in a single arm phase II study in...
Autor:
Ashley Chasick, Robert Emmons, Elizabeth Ellent, Qingyang Luo, Sachin Gopalkrishn Pai, Charles V. Wendling
Publikováno v:
Journal of Clinical Oncology. 33:e18014-e18014
e18014 Background: Melphalan at 200 mg/m2 has been an established conditioning regimen in patients undergoing autologous hematopoietic stem cell transplant (ASCT) with Multiple Myeloma (MM). There ...
Publikováno v:
Journal of Clinical Oncology. 33:56-56
56 Background: Barrett’s esophagus is a well-known risk factor for esophageal cancer. Surveillance esophagogastroduodenoscopy (EGD) and procedures like endoscopic mucosal resection (EMR) and radio frequency ablation (RFA) are adopted to mitigate ri